biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by TechnicalBuyon Aug 16, 2011 10:36am

258 Views

Post# 18946979

RE: ring ring... ring ring.... ring ring

hahahaha

Not likely to happen today drj, but certainly on the right track. The beauty is that the POC only takes about 2 months for Bioasis to complete. So we may not be too far away from the phone call you described. Though I'm sure the phone is ringing off the hook for pharmas wanting to send their r&d folks to take a good look at p97 asap.

TB
technicalbuy.com

Bullboard Posts

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta